BIA Head Attacks Rapporteur Reallocation, But Welcomes Further Clarity On Transition Period
Executive Summary
Steve Bates, CEO of the BIA, is concerned that the EU authorities are overloading national regulatory agencies by reallocating UK rapporteurships to other member states before they are ready to take them on. However, he has welcomed clarification from the UK government over the movement of medicines during any Brexit transitional period.
You may also be interested in...
EMA Redistributes Responsibility For 370 Drugs Currently Overseen By UK
The EMA has completed the reallocation to the EU27 member states of more than 370 centrally authorized drugs for which the UK was rapporteur or co-rapporteur. The move has been necessitated by Brexit, which means the UK will no longer play an active role in new drug evaluations at the EMA.
French HTA Body Backs Routine Six-Week Interval In COVID-19 Vaccine Dosing
France's health technology assessment body says that delaying by six weeks the second dose of the two mRNA vaccines approved for use against COVID-19 would allow at least 700,000 more people to receive their jab in the first month.
Coronavirus Notebook: EU Publishes CureVac Vaccine Contract, AZ and Pfizer Under Attack Over Supply Cuts
The European Ombudsman has opened an inquiry regarding the disclosure of vaccine contracts with other companies, and the European Commission is planning a “sharing mechanism” for vaccines bought by EU member states.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: